Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

Johnson & Johnson announced the U.S. FDA approved DARZALEX FASPRO as a single agent treatment for adult patients with high-risk smoldering ...

Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for ...

The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...

People with extreme, life-threatening allergic reactions might do as well to use a nasal spray as to jab themselves in a ...

Johnson & Johnson (JNJ) stock is in focus as the FDA further expands the labeling for its antipsychotic to treat adults with ...

Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance ...